Flex Pharma shareholders OK reverse-merger after drug failure

Shareholders have approved a plan making Flex Pharma, the neurobiology-focused biotech started five years ago by a Nobel Prize winner and one of the founders of Alnylam Pharmaceuticals Inc., into a shell company for a privately held Houston cancer drug developer.   Flex Pharma (Nasdaq: FLKS) was co-founded in 2014 by Nobel Prize Winner Rod MacKinnon and serial entrepreneur Christoph Westphal. The company began looking for a merger partner after its “tolerability concerns” arose during a mid-stage…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news